XRTX report from LinkedIn:
We are pleased to bring investors the new, special report by The Venture Letter™ venture stock newsletter on XORTX Therapeutics Inc. (NASDAQ & TSXV: XRTX), officially released last week. https://theventureletter.com/wp-content/uploads/2024/02/TVL-Special-Report-XORTX-Therapeutics-Inc.-0224.pdf[/tag]
We are excited by the prospects for XORTX and the company’s efforts to provide new and much-needed orphan drug therapy to slow progressive kidney disease.
We invite everyone to read our special report and take a close look at XORTX Therapeutics, now approaching its third and most important FDA drug trial. Biotech stocks are in a bull market right now and we see XRTX as a perfect company to investigate.
Good luck and good hunting.
#theventureletter #stocksinfocus #XORTX #XRTX #biotech #biotechs #biotechstocks #XBI #nasdaqlisted #stocks